Drugs / 4-Methylpyrazole
4-Methylpyrazole
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00346853 | Nov 2005 → May 2006 | macular corneal dystrophy | University of Utah | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-Methylpyrazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00346853 ↗ |
| Known as | 4-MP | “4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye.” NCT00346853 ↗ |
| Known as | Antizol | “4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye.” NCT00346853 ↗ |
| Known as | fomepizole | “4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye.” NCT00346853 ↗ |
| Action | Inhibit | “an alcohol dehydrogenase inhibitor” PMID 17963111 ↗ Oct 2007 |
| Route | Intravenous | “Healthy adults were given intravenous infusions of either 4-MP or placebo” PMID 17963111 ↗ Oct 2007 |